Clinical Assessment of Mocravimod As a Victim of Drug-Drug Interactions Via CYP3A Metabolism and Transporters

被引：0
|
作者：
Huntjens, Dymphy [1 ]
Oehen, Stephan [2 ]
Kueenburg, Elisabeth [3 ]
机构：
[1] Priothera SAS, Valkenburg, Netherlands
[2] Priothera SAS, Basel, Switzerland
[3] Priothera SAS, St Louis, France
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-193899
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5774 / 5775
页数：2
相关论文
共 50 条
  • [41] Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies
    Bolleddula, Jayaprakasam
    Gopalakrishnan, Sathej
    Hu, Ping
    Dong, Jennifer
    Venkatakrishnan, Karthik
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (09): : 2075 - 2095
  • [42] Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
    Yalkinoglu, Oe.
    Heuer, J.
    Becker, A.
    Krebs-Brown, A.
    Strotmann, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] PBPK MODELING TO ASSESS DRUG-DRUG INTERACTION POTENTIAL OF VENGLUSTAT WITH CYP3A INHIBITORS
    Sharma, J.
    Li, L.
    Macha, S.
    Xu, C.
    Sahi, J.
    Zhang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S74 - S74
  • [44] Gugulipid, CYP3A, and herb-drug interactions
    Brobst, DE
    Ding, XS
    Goodwin, BJ
    Staudinger, JL
    DRUG METABOLISM REVIEWS, 2003, 35 : 119 - 119
  • [45] Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
    Fukumura, Kazuya
    Kawaguchi, Nao
    Ishibashi, Toru
    Kubota, Ryuji
    Tada, Yukio
    Ogura, Eriko
    CLINICAL DRUG INVESTIGATION, 2020, 40 (06) : 529 - 540
  • [46] Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
    Kazuya Fukumura
    Nao Kawaguchi
    Toru Ishibashi
    Ryuji Kubota
    Yukio Tada
    Eriko Ogura
    Clinical Drug Investigation, 2020, 40 : 529 - 540
  • [47] Variability in drug transporters: Genetic polymorphism and drug-drug interactions
    Sugiyama, Y
    DRUG METABOLISM REVIEWS, 2005, 37 : 2 - 3
  • [48] Epidemiology of CYP3A4-Mediated Clopidogrel Drug-Drug Interactions and Their Clinical Consequences
    Tirkkonen, Tuire
    Heikkila, Pekka
    Vahlberg, Tero
    Huupponen, Risto
    Laine, Kari
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (06) : 344 - 351
  • [49] MOCRAVIMOD DOES NOT HAVE A CLINICALLY RELEVANT DRUG-DRUG INTERACTION WITH STRONG CYP3A4 INHIBITOR ITRACONAZOLE
    Huntjens, Dymphy
    Oehen, Stephan
    Kueenburg, Elisabeth
    BONE MARROW TRANSPLANTATION, 2024, 59 : 740 - 741
  • [50] In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet
    Greenblatt, D. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (02) : 133 - 135
12345